End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
17.95 CNY | -0.06% | -1.05% | -20.50% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-20.50% | 2.22B | D+ | ||
+22.39% | 43.96B | B | ||
-0.30% | 18.75B | B- | ||
+25.60% | 2.11B | C+ | ||
+19.17% | 1.13B | - | ||
-38.32% | 716M | - | ||
-10.65% | 645M | - | ||
-44.53% | 632M | B- | ||
+57.22% | 606M | - | - | |
+17.51% | 494M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 300595 Stock
- Ratings Autek China Inc.